Almond, S. & O'Donnell, O. (2000) Cost analysis of the treatment of schizophrenia in the UK: a simulation model comparing olanzapine risperidone and haloperidol. Pharmacoeconomics, 17, 383–389.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA.
Bagnall, A. M., Jones, L., Ginnelly, L., et. al (2003) A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment, 7, 1–204.
Bobes, J., Garcfa-Portilla, P., Sfiiz, P. A., et al (2005) Quality of life measures in schizophrenia. European Psychiatry, 20, S313–S317
Briggs, A. H. & O'Brien, B. J. (2001) The death of cost minimisation analysis?
Health Economics, 10, 179–184.
Briggs, A. H., O'Brien, B. J., Blackhouse, G. (2002) Recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health, 23, 377–401.
British Medical Association & Royal Pharmaceutical Society of Great Britain (2002) British National Formulary (issue 44). BMJ Books & Pharmaceutical Press.
Chartered Institute of Public Finance Accountants (2002) The CIPFA Database 2002. CIPFA.
Davies, L. & Lewis, S. (2000) Antipsychotic Medication for People with Schizophrenia: An Exploratory Economic Analysis of Alternative Treatment Algorithms. Discussion Paper 178. University of York, Centre for Health Economics.
Dolan, P., Gudex, C., Kind, P., et al (1995) A Social Tarifffor EuroQuo: Results from a UK General Population Survey. Discussion Paper 138. University of York, Centre for Health Economics.
Fenwick, E., Claxton, K. & Sculpher, M. (2001) Representing uncertainty. The role of cost-effectiveness acceptability curves. Health Economics, 10, 779–787.
Geddes, J., Freemantle, N., Harrison, P., et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 321, 1371–1376.
Gianfrancesco, F., Durkin, M. B., Mahmoud, R., et al (2002) Use of health care services by patients treated with risperidone versus conventional antipsychotic agents. Pharmacoeconomics, 20, 413–427.
Gold, M. R., Siegel, J. E., Russell, L. B., et al (1996) Cost Effectiveness in Health and Medicine. Oxford University Press.
Gregor, K. J., Allicar, M. P., Lilliu, H., et al (2000) An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France. Schizophrenia Research, 41, 189–190.
Heinrichs, D. W., Hanlon, T. E. & Carpenter, W. T. (1984) The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10, 388–398.
Hoch, J. S., Briggs, A. H. & Willan, A. R. (2002) Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics, 11, 415–430.
Hosak, L. & Bahbouh, R. (2002) Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic. European Psychiatry, 17, 213–221.
Jones, P. B., Davies, L. M., Barnes, T. R. E., et al (2006) Randomized controlled trial of effect on quality of life of second generation versus first generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry, 63, 1079–1087.
Kilian, R., Dietrich, M., Toumi, M., et al (2004) Quality of life in persons with schizophrenia in outpatient treatment with first- or second-generation antipsychotics. Acta Psychiatrica Scandinavica, 110, 108–118.
Kind, P. (1996) The EuroQoL instrument: an index of health related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn (ed. Spilker, B.). Lippincott-Raven.
Knapp, M., Ilson, S. & David, A. (2002) Depot preparations in schizophrenia: the state of the economic evidence. International Clinical Psychopharmacology, 17, 135–140.
Lavori, P. W., Dawson, R. & Shera, D. (1995) A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine, 14, 1913–1925.
Lewis, M., McCrone, P., Frangou, S., et al (2001) Service use and costs of treating schizophrenia with atypical antipsychotics. Journal of Clinical Psychiatry, 62, 749–756.
Lieberman, J. A. (2006) Comparative effectiveness of antipsychotic drugs: a commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS I) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Archives of General Psychiatry, 63, 1069–1072.
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al (2005) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine, 353, 1209–1223.
Lloyd, H. M., Markwick, A. J., Page, E. R., et al (2005) Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the CUtLASS study. International Journal of Psychiatry in Clinical Practice, 9, 35–40.
Lynch, J., Morrison, J., Graves, N., et al (2001) The health economic implications of treatment with quetiapine: an audit of long term treatment for patients with chronic schizophrenia. European Psychiatry, 16, 307–312.
Martin, B. C., Miller, L. S. & Kotzan, J. A. (2001) Antipsychotic prescription use and costs for persons with schizophreniain the 1990s: current trends and five year time series forecasts. Schizophrenia Research, 47, 281–292.
National Institute for Clinical Excellence (2004) Guide to the Methods of Technology Appraisal. NO515. NICE.
Netten, A. & Curtis, L. (2002) Unit Costs of Health and Social Care. University of Kent, Personal Social Services Research Unit.
O'Brien, B. J. & Briggs, A. H. (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research, 11, 455–468.
Oh, P. I., Lanctot, K. L., Mittmann, N., et al (2001) Cost utility analysis of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. Journal of Medical Economics, 4, 137–156.
Palmer, C. S., Brunner, E., Ruiz-Flores, L. G., et al (2002) A cost effectiveness decision analysis model for treatment of schizophrenia. Archives of Medical Research, 33, 572–580.
Pedram-Sendi, P. & Briggs, A. H. (2001) Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Economics, 10, 675–680.
Prieto, L., Novick, D., Sacristan, J. A., et al (2003) A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatrica Scandinavica Supplementum, 416, 24–29.
Rawlins, M. D. & Culyer, A. J. (2004) National Institute for Clinical Excellence and its value judgments. BMJ, 329, 224–227.
Rosenheck, R., Perlick, D., Bingham, S., et al (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA, 290, 2693–2702.
Rubin, D. B. & Schenker, N. (1991) Multiple imputation in health-care databases: an overview and some applications. Statistics in Medicine, 10, 585–598.
Tilden, D., Aristedes, M., Meddis, D., et al (2002) An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clinical Therapeutics, 24, 1648–1667.